newsbot.ch News https://www.newsbot.ch Die neusten Nachrichten auf newsbot.ch de-de Redaktion redaktion@content-provider.ch Wed, 21 Aug 2019 09:08:48 +0000 Graphen-Nanoflocken: ein neues Instrument für die Präzisionsmedizin ​Normalerweise verbreitet sich ein Medikament im ganzen Körper, weshalb ein Grossteil das kranke Gewebe nicht erreicht. Die Präzisionsmedizin soll unter anderem die Effizienz von Wirkstoffen erhö https://www.newsbot.ch/news/45309/Wissenschaft/Graphen-Nanoflocken--ein-neues-Instrument-fuer-die-Praezisionsmedizin https://www.newsbot.ch/news/45309/Wissenschaft/Graphen-Nanoflocken--ein-neues-Instrument-fuer-die-Praezisionsmedizin 2019-08-20 22:55:08 FDA approves Roche’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). https://www.newsbot.ch/news/45079/Wirtschaft/FDA-approves-Roche’s-Rozlytrek-entrectinib-for-people-with-ROS1-positive-metastatic-non-small-cell-lung-cancer-and-NTRK-gene-fusion-positive-solid-tumours https://www.newsbot.ch/news/45079/Wirtschaft/FDA-approves-Roche’s-Rozlytrek-entrectinib-for-people-with-ROS1-positive-metastatic-non-small-cell-lung-cancer-and-NTRK-gene-fusion-positive-solid-tumours 2019-08-16 16:40:40 Erste Quartierküche: 650 Mahlzeiten pro Tag für Berner Kinder In der Küche des ehemaligen Zieglerspitals ist die erste Quartierküche der Stadt Bern entstanden. Sie versorgt seit Beginn des neuen Schuljahres 2019/20 insgesamt 19 Tagesschulen, Kitas und Tagis mi https://www.newsbot.ch/news/44998/Regional/Erste-Quartierkueche--650-Mahlzeiten-pro-Tag-fuer-Berner-Kinder https://www.newsbot.ch/news/44998/Regional/Erste-Quartierkueche--650-Mahlzeiten-pro-Tag-fuer-Berner-Kinder 2019-08-15 10:32:00 1. August Empfang in der Orangerie Elfenau (English/Français) https://www.newsbot.ch/news/44564/Regional/1-August-Empfang-in-der-Orangerie-Elfenau-English-Français https://www.newsbot.ch/news/44564/Regional/1-August-Empfang-in-der-Orangerie-Elfenau-English-Français 2019-08-06 16:02:01 Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer Roche today announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS). https://www.newsbot.ch/news/44475/Wirtschaft/Roche’s-Tecentriq-plus-platinum-based-chemotherapy-reduced-the-risk-of-disease-worsening-or-death-in-people-with-previously-untreated-advanced-bladder-cancer https://www.newsbot.ch/news/44475/Wirtschaft/Roche’s-Tecentriq-plus-platinum-based-chemotherapy-reduced-the-risk-of-disease-worsening-or-death-in-people-with-previously-untreated-advanced-bladder-cancer 2019-08-05 05:40:23 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding https://www.newsbot.ch/news/44356/Wirtschaft/Roche-and-Spark-Therapeutics-Inc-announce-extension-of-tender-offer-for-shares-of-Spark-Therapeutics-Inc https://www.newsbot.ch/news/44356/Wirtschaft/Roche-and-Spark-Therapeutics-Inc-announce-extension-of-tender-offer-for-shares-of-Spark-Therapeutics-Inc 2019-07-31 09:24:45 Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer Roche today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination wi https://www.newsbot.ch/news/44189/Wirtschaft/Roche-receives-CHMP-positive-opinion-for-new-Tecentriq-based-combination-therapy-as-an-initial-treatment-for-most-common-form-of-advanced-lung-cancer https://www.newsbot.ch/news/44189/Wirtschaft/Roche-receives-CHMP-positive-opinion-for-new-Tecentriq-based-combination-therapy-as-an-initial-treatment-for-most-common-form-of-advanced-lung-cancer 2019-07-26 11:20:11 CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer Roche today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination wi https://www.newsbot.ch/news/44190/Wirtschaft/CHMP-recommends-EU-approval-of-Roche’s-Tecentriq-in-combination-with-chemotherapy-as-an-initial-treatment-of-adults-with-extensive-stage-small-cell-lung-cancer https://www.newsbot.ch/news/44190/Wirtschaft/CHMP-recommends-EU-approval-of-Roche’s-Tecentriq-in-combination-with-chemotherapy-as-an-initial-treatment-of-adults-with-extensive-stage-small-cell-lung-cancer 2019-07-26 11:20:11 Roche mit sehr gutem Ergebnis im ersten Halbjahr 2019 – Ausblick angehoben Konzernverkäufe steigen um 9% zu konstanten Wechselkursen und 8% in Schweizer Franken https://www.newsbot.ch/news/44112/Wirtschaft/Roche-mit-sehr-gutem-Ergebnis-im-ersten-Halbjahr-2019---Ausblick-angehoben https://www.newsbot.ch/news/44112/Wirtschaft/Roche-mit-sehr-gutem-Ergebnis-im-ersten-Halbjahr-2019---Ausblick-angehoben 2019-07-25 05:40:00 Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress Roche today announced new data for Hemlibra® (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombos https://www.newsbot.ch/news/43434/Wirtschaft/Roche-presents-a-broad-range-of-data-for-Hemlibra-demonstrating-continued-benefits-for-people-with-haemophilia-A-at-the-ISTH-2019-Congress https://www.newsbot.ch/news/43434/Wirtschaft/Roche-presents-a-broad-range-of-data-for-Hemlibra-demonstrating-continued-benefits-for-people-with-haemophilia-A-at-the-ISTH-2019-Congress 2019-07-09 09:20:15